Phenotypes associated with this allele
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Gt(ROSA)26Sortm1(gp80,EGFP)Eces mutation
(0 available);
any
Gt(ROSA)26Sor mutation
(811 available)
Ighg1tm1(cre)Cgn mutation
(3 available);
any
Ighg1 mutation
(13 available)
|
|
|
Splenomegaly and lack of germinal center formation in Gt(ROSA)26Sortm1(gp80,EGFP)Eces/Gt(ROSA)26Sor+ Cd19tm1(cre)Cgn/Cd19+ (left) and Gt(ROSA)26Sortm1(gp80,EGFP)Eces/Gt(ROSA)26Sor+ Ighg1tm1(cre)Cgn/Ighg1+ mice (right)
growth/size/body
|
|
• in non-immunized and immunized mice starting at 2 to 3 months of age
|
mortality/aging
|
|
• mice succumb to tumors between 7 and 19 months of age
|
immune system
|
|
• in non-immunized and immunized mice starting at 2 to 3 months of age
|
|
|
• mice exhibit fewer IgG1+ B cells compared to in wild-type mice
|
|
|
• in the spleen with a slight reduction in the splenic B to T cell ratio
|
|
|
• in non-immunized and immunized mice
|
|
|
• resting and NP-stimulated
|
|
|
• resting and NP-stimulated
|
|
|
• resting and NP-stimulated
|
|
|
• resting and NP-stimulated
|
|
|
• resting and NP-stimulated
|
neoplasm
|
|
• mice develop tumors in lymphoid tissues including nasopharynx, armpit, and inguinal region
|
|
|
• histocytic/dendritic cell sarcoma
|
hematopoietic system
|
|
• in non-immunized and immunized mice starting at 2 to 3 months of age
|
|
|
• mice exhibit fewer IgG1+ B cells compared to in wild-type mice
|
|
|
• in the spleen with a slight reduction in the splenic B to T cell ratio
|
|
|
• in non-immunized and immunized mice
|
|
|
• resting and NP-stimulated
|
|
|
• resting and NP-stimulated
|
|
|
• resting and NP-stimulated
|
|
|
• resting and NP-stimulated
|
|
|
• resting and NP-stimulated
|
cellular
|
|
• reduced germinal center B cell compartment proliferation following injection of antigen sheep red blood cells
|
immune system
|
N |
• mice exhibit normal marginal zone and follicular B cells
|
|
|
• reduced germinal center B cell compartment proliferation following injection of antigen sheep red blood cells
|
|
|
• following injection of antigen sheep red blood cells or immunization with NP-KLH
|
|
|
• following injection of antigen sheep red blood cells
|
|
|
• following injection of antigen sheep red blood cells
|
|
|
• following immunization with NP-KLH
|
|
|
• following immunization with NP-KLH
|
|
|
• following immunization with NP-KLH
|
hematopoietic system
|
|
• reduced germinal center B cell compartment proliferation following injection of antigen sheep red blood cells
|
|
|
• following injection of antigen sheep red blood cells or immunization with NP-KLH
|
|
|
• following injection of antigen sheep red blood cells
|
|
|
• following injection of antigen sheep red blood cells
|
|
|
• following immunization with NP-KLH
|
|
|
• following immunization with NP-KLH
|
|
|
• following immunization with NP-KLH
|
immune system
|
N |
• mice form germinal centers and have similar numbers of PNAhi, B220+ B cells in spleen
|
|
|
• following CD40 and Il-4 stimulation, mice have smaller fraction of class-switched cells than control mice (7.4% vs 26.3%); defect appears to be downstream of Cgamma1 germline transcription
|
|
|
• 14 days after immunization with sheep red blood cells, mutants are observed to lack plasma cells, as recognized by CD138 expression, in spleen, peripheral blood and bone marrow
|
|
|
• memory B cell generation occurs in mutants after immunization with NP-KLH, but the population is maintained only partly over time; numbers of NP-binding cells are much lower 42 days after immunization compared to controls
• mice receiving a secondary immunization with antigen lack plasmablasts in the spleen that bind NP, are CD138 +ve and have low B220 expression, indicating that memory B cells cannot differentiate into plasma B cells upon antigen restimulation; B cells also lack IgG1 secretion after restimulation
|
|
|
• mice have much lower titer of IgG1 specific for the hapten NP (nitrophenylacetyl) than controls after immunization with NP coupled to keyhole limpet hemocyanin, but titers of other immunoglobulin classes are similar to levels in controls
|
hematopoietic system
|
|
• following CD40 and Il-4 stimulation, mice have smaller fraction of class-switched cells than control mice (7.4% vs 26.3%); defect appears to be downstream of Cgamma1 germline transcription
|
|
|
• 14 days after immunization with sheep red blood cells, mutants are observed to lack plasma cells, as recognized by CD138 expression, in spleen, peripheral blood and bone marrow
|
|
|
• memory B cell generation occurs in mutants after immunization with NP-KLH, but the population is maintained only partly over time; numbers of NP-binding cells are much lower 42 days after immunization compared to controls
• mice receiving a secondary immunization with antigen lack plasmablasts in the spleen that bind NP, are CD138 +ve and have low B220 expression, indicating that memory B cells cannot differentiate into plasma B cells upon antigen restimulation; B cells also lack IgG1 secretion after restimulation
|
|
|
• mice have much lower titer of IgG1 specific for the hapten NP (nitrophenylacetyl) than controls after immunization with NP coupled to keyhole limpet hemocyanin, but titers of other immunoglobulin classes are similar to levels in controls
|
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1tm1(CAG-Ezh2*)Meln mutation
(0 available);
any
Col1a1 mutation
(140 available)
Ighg1tm1(cre)Cgn mutation
(3 available);
any
Ighg1 mutation
(13 available)
|
|
|
immune system
|
N |
• mice exhibit normal marginal zone and follicular B cells
|
|
|
• following immunization with NP-KLH
|
|
|
• following immunization with NP-KLH
|
|
|
• following immunization with NP-KLH
|
neoplasm
|
N |
• mice exhibit normal marginal zone and follicular B cells
|
hematopoietic system
|
|
• following immunization with NP-KLH
|
|
|
• following immunization with NP-KLH
|
|
|
• following immunization with NP-KLH
|
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Gt(ROSA)26Sortm12(CD2*)Rsky mutation
(0 available);
any
Gt(ROSA)26Sor mutation
(811 available)
Ighg1tm1(cre)Cgn mutation
(3 available);
any
Ighg1 mutation
(13 available)
Myctm2Fwa mutation
(2 available);
any
Myc mutation
(33 available)
|
|
|
immune system
|
|
• almost complete ablation of germinal centers in response to T cell dependent immunization
• the few remaining germinal center B cells have escaped cre mediated recombination
|
hematopoietic system
|
|
• almost complete ablation of germinal centers in response to T cell dependent immunization
• the few remaining germinal center B cells have escaped cre mediated recombination
|
immune system
|
N |
• enforced expression of human MYC rescues germinal center formation
|
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Ighg1tm1(cre)Cgn mutation
(3 available);
any
Ighg1 mutation
(13 available)
Mef2btm1.1Rdf mutation
(0 available);
any
Mef2b mutation
(14 available)
Mef2ctm2Eno mutation
(0 available);
any
Mef2c mutation
(20 available)
|
|
|
hematopoietic system
|
|
• 14 days after immunization with sheep red blood cells (SRBCs)
|
immune system
|
|
• 14 days after immunization with sheep red blood cells (SRBCs)
|
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Ighg1tm1(cre)Cgn mutation
(3 available);
any
Ighg1 mutation
(13 available)
Mef2ctm2Eno mutation
(0 available);
any
Mef2c mutation
(20 available)
|
|
|
hematopoietic system
|
|
• 14 days after immunization with sheep red blood cells (SRBCs)
|
immune system
|
|
• 14 days after immunization with sheep red blood cells (SRBCs)
|
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Ighg1tm1(cre)Cgn mutation
(3 available);
any
Ighg1 mutation
(13 available)
Mef2dtm3Eno mutation
(0 available);
any
Mef2d mutation
(57 available)
|
|
|
hematopoietic system
|
N |
• normal spleen germinal center (GC) B cell numbers 14 days after immunization with sheep red blood cells (SRBCs)
|
growth/size/body
|
|
• hepatomegaly in one mouse
|
|
|
• splenomegaly in all terminally ill mice
|
hematopoietic system
|
|
• splenomegaly in all terminally ill mice
|
|
|
• plasma cell formation is severely impeded 10 days after primary and secondary immunization
|
|
|
• mice show increased numbers of germinal center B cells at day 10 after primary immunizations
|
|
|
• small, but significant, increase of the fraction of germinal center B cells in the S and G2 phases of the cell cycle
|
|
|
• reduction in total as well as sheep red blood cell-specific IgG1, but not IgM, antibodies 10 days after primary and secondary immunization
|
immune system
|
|
• splenomegaly in all terminally ill mice
|
|
|
• plasma cell formation is severely impeded 10 days after primary and secondary immunization
|
|
|
• mice show increased numbers of germinal center B cells at day 10 after primary immunizations
|
|
|
• small, but significant, increase of the fraction of germinal center B cells in the S and G2 phases of the cell cycle
|
|
|
• reduction in total as well as sheep red blood cell-specific IgG1, but not IgM, antibodies 10 days after primary and secondary immunization
|
|
|
• occasional lymphadenopathy
|
liver/biliary system
|
|
• hepatomegaly in one mouse
|
mortality/aging
neoplasm
|
|
• spleens and lymph nodes show presence of large cells with a diffuse growth pattern, resembling diffuse large B cell lymphoma (DLBCL)
• lymphoproliferations are of clonal origin
• 5 of 6 DLBCLs are consistent with activated B cell-DLBCL
|
immune system
 N |
• unimmunized mice exhibit normal germinal center size and number, IgG1+ B cell numbers, plasma cells, total IgG1 serum levels and induced B cell proliferation
|
mortality/aging
|
|
• when bone marrow is used to reconstitute Rag2 and Il2rg null mice stimulated with sheep red blood cells, median survival is 227 days
|
immune system
|
|
• in the Peyer's patches and spleen
|
neoplasm
|
|
• of germinal center B cell origin when bone marrow is used to reconstitute Rag2 and Il2rg null mice stimulated with sheep red blood cells
|
hematopoietic system
|
|
• in the Peyer's patches and spleen
|
growth/size/body
|
|
• enlarged spleens in mice 550-600 days of age
|
hematopoietic system
|
|
• mice show some reduction in the germinal center B cell fraction at day 10 after primary and secondary immunization
|
|
|
• hyperplasia of B cells in the spleen and bone marrow at 550-600 days
|
|
|
• hyperplasia of plasma cells in the spleen and bone marrow at 550-600 days
• clonal or oligoclonal plasma cell expansions
|
|
|
• large numbers of cells expressing intracellular Ig and the plasma cell marker CD138 are seen in spleens
|
|
|
• enlarged spleens in mice 550-600 days of age
|
immune system
|
|
• mice show some reduction in the germinal center B cell fraction at day 10 after primary and secondary immunization
|
|
|
• hyperplasia of B cells in the spleen and bone marrow at 550-600 days
|
|
|
• hyperplasia of plasma cells in the spleen and bone marrow at 550-600 days
• clonal or oligoclonal plasma cell expansions
|
|
|
• large numbers of cells expressing intracellular Ig and the plasma cell marker CD138 are seen in spleens
|
|
|
• enlarged spleens in mice 550-600 days of age
|
hematopoietic system
|
|
• plasma cell formation is severely impeded 10 days after primary and secondary immunization
|
|
|
• mice show increased numbers of germinal center B cells at day 10 after primary immunizations
|
|
|
• small, but significant, increase of the fraction of germinal center B cells in the S and G2 phases of the cell cycle
|
|
|
• reduction in total as well as sheep red blood cell-specific IgG1, but not IgM, antibodies 10 days after primary and secondary immunization
|
immune system
|
|
• plasma cell formation is severely impeded 10 days after primary and secondary immunization
|
|
|
• mice show increased numbers of germinal center B cells at day 10 after primary immunizations
|
|
|
• small, but significant, increase of the fraction of germinal center B cells in the S and G2 phases of the cell cycle
|
|
|
• reduction in total as well as sheep red blood cell-specific IgG1, but not IgM, antibodies 10 days after primary and secondary immunization
|
mortality/aging
|
|
• shortened survival, with 40% survival at around 500 days of age
|
neoplasm
|
|
• mice succumb to a B cell-derived lymphoproliferative disease affecting spleen and lymph nodes, resembling human diffuse large B cell lymphoma
• mice develop clonal lymphomas consistent with activated B cell-diffuse large B cell lymphoma
|
immune system
|
|
• mild day 28 post immunization with sheep red blood cells
|
|
|
• mild day 28 post immunization with sheep red blood cells
|
hematopoietic system
|
|
• mild day 28 post immunization with sheep red blood cells
|
|
|
• mild day 28 post immunization with sheep red blood cells
|
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Ighg1tm1(cre)Cgn mutation
(3 available);
any
Ighg1 mutation
(13 available)
Mef2btm1.1Rdf mutation
(0 available);
any
Mef2b mutation
(14 available)
|
|
|
hematopoietic system
|
|
• decreased GC B cell number 10 days after immunization with sheep red blood cells (SRBCs)
• smaller GC B cells 10 days after immunization with sheep red blood cells (SRBCs)
• normal follicular and marginal zone B cell numbers 10 days after immunization with sheep red blood cells (SRBCs)
|
|
|
• 10 days after immunization with sheep red blood cells (SRBCs)
• reduced dark zone (DZ)/light zone (LZ) ratio owing to reduced number of cells in DZ
|
immune system
|
|
• smaller GC B cells 10 days after immunization with sheep red blood cells (SRBCs)
• decreased GC B cell number 10 days after immunization with sheep red blood cells (SRBCs)
• normal follicular and marginal zone B cell numbers 10 days after immunization with sheep red blood cells (SRBCs)
|
|
|
• 10 days after immunization with sheep red blood cells (SRBCs)
• reduced dark zone (DZ)/light zone (LZ) ratio owing to reduced number of cells in DZ
|
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Ighg1tm1(cre)Cgn mutation
(3 available);
any
Ighg1 mutation
(13 available)
Mef2btm1.1Rdf mutation
(0 available);
any
Mef2b mutation
(14 available)
|
|
|
hematopoietic system
|
|
• modest reduction in number 10 days after immunization with sheep red blood cells (SRBCs)
• reduced dark zone (DZ)/light zone (LZ) ratio owing to reduced number of cells in DZ
|
immune system
|
|
• modest reduction in number 10 days after immunization with sheep red blood cells (SRBCs)
• reduced dark zone (DZ)/light zone (LZ) ratio owing to reduced number of cells in DZ
|
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Ighg1tm1(cre)Cgn mutation
(3 available);
any
Ighg1 mutation
(13 available)
Mef2btm1.1Rdf mutation
(0 available);
any
Mef2b mutation
(14 available)
Mef2btm2Rdf mutation
(0 available);
any
Mef2b mutation
(14 available)
|
|
|
hematopoietic system
|
|
• increased GC B cell number 10 days after immunization with sheep red blood cells (SRBCs)
• larger GC B cells 10 days after immunization with sheep red blood cells (SRBCs)
• normal non-GC B cell numbers 10 days after immunization with sheep red blood cells (SRBCs)
|
|
|
• 10 days after immunization with sheep red blood cells (SRBCs)
|
immune system
|
|
• increased GC B cell number 10 days after immunization with sheep red blood cells (SRBCs)
• larger GC B cells 10 days after immunization with sheep red blood cells (SRBCs)
• normal non-GC B cell numbers 10 days after immunization with sheep red blood cells (SRBCs)
|
|
|
• 10 days after immunization with sheep red blood cells (SRBCs)
|
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Ighg1tm1(cre)Cgn mutation
(3 available);
any
Ighg1 mutation
(13 available)
Mef2btm2Rdf mutation
(0 available);
any
Mef2b mutation
(14 available)
|
|
|
hematopoietic system
|
|
• increased GC B cell number 10 days after immunization with sheep red blood cells (SRBCs)
• larger GC B cells 10 days after immunization with sheep red blood cells (SRBCs)
• normal non-GC B cell numbers 10 days after immunization with sheep red blood cells (SRBCs)
|
|
|
• 10 days after immunization with sheep red blood cells (SRBCs)
• reduced dark zone (DZ)/light zone (LZ) ratio owing to reduced number of cells in DZ and increased number in LZ
|
immune system
|
|
• increased GC B cell number 10 days after immunization with sheep red blood cells (SRBCs)
• larger GC B cells 10 days after immunization with sheep red blood cells (SRBCs)
• normal non-GC B cell numbers 10 days after immunization with sheep red blood cells (SRBCs)
|
|
|
• 10 days after immunization with sheep red blood cells (SRBCs)
• reduced dark zone (DZ)/light zone (LZ) ratio owing to reduced number of cells in DZ and increased number in LZ
|
mortality/aging
|
|
• mice die around 13 months of age as in Tg(Vav-BCL2)1Jad mice
|
neoplasm
|
|
• diffuse large B cell lymphoma as in Tg(Vav-BCL2)1Jad mice
|
|
|
• more so than in Tg(Vav-BCL2)1Jad mice
|
mortality/aging
|
|
• mice die around 13 months of age as in Tg(Vav-BCL2)1Jad mice
|
neoplasm
|
|
• diffuse large B cell lymphoma more so than in Tg(Vav-BCL2)1Jad mice
|
|
|
• more so than in Tg(Vav-BCL2)1Jad mice
|
immune system
|
N |
• mice immunized with NP-CG exhibit normal development of memory B cells
|
|
|
• in mice immunized with NP-CG at day 7 and 40 with deletion of early GC B cells
|
hematopoietic system
|
|
• in mice immunized with NP-CG at day 7 and 40 with deletion of early GC B cells
|
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Gm614tm1.1Cya mutation
(0 available);
any
Gm614 mutation
(5 available)
Ighg1tm1(cre)Cgn mutation
(3 available);
any
Ighg1 mutation
(13 available)
|
|
|
immune system
|
N |
• normal total IgG levels after pristane injection
• normal CD86loCXCR4hi dark zone (DZ) and CD86hiCXCR4lo light zone (LZ) B cells ratio after pristane injection
• normal B cell cell cycle after pristane injection
|
|
|
• in germinal center after pristane injection
|
|
|
• reduced inflammatory cell infiltration in kidney and normal glomerular morphology after pristane injection
• reduced levels of IgM and IgG anti-nucleic antibodies and anti-nucleosome IgG after pristane injection
|
hematopoietic system
|
|
• in germinal center after pristane injection
|
cellular
|
|
• in germinal center after pristane injection
|
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Ighg1tm1(cre)Cgn mutation
(3 available);
any
Ighg1 mutation
(13 available)
Myd88em1.1Rsky mutation
(0 available);
any
Myd88 mutation
(42 available)
|
|
|
hematopoietic system
|
N |
• normal Ig class switching in germinal center B cells after immunization with hapten-carrier conjugate NP-CGG
• normal rise and fall of hapten-specific IgG levels after immunization with hapten-carrier conjugate NP-CGG
|
|
|
• increased frequency in IgM+ plasma cells
|
|
|
• increased frequency and number
|
|
|
• persistently high number of hapten-specific IgM+ plasma cells in spleen and bone marrow for at least 50 weeks after immunization with hapten-carrier conjugate NP-CGG
• high total plasma cell numbers in spleen and bone marrow for at least 50 weeks after immunization with hapten-carrier conjugate NP-CGG
|
|
|
• increased frequency and number of plasma cells and germinal center B cells
|
|
|
• high total IgM serum levels for at least 50 weeks after immunization with hapten-carrier conjugate NP-CGG
• persistently high hapten-specific IgM levels for at least 50 weeks after immunization with hapten-carrier conjugate NP-CGG
|
immune system
|
|
• increased frequency in IgM+ plasma cells
|
|
|
• increased frequency and number
|
|
|
• persistently high number of hapten-specific IgM+ plasma cells in spleen and bone marrow for at least 50 weeks after immunization with hapten-carrier conjugate NP-CGG
• high total plasma cell numbers in spleen and bone marrow for at least 50 weeks after immunization with hapten-carrier conjugate NP-CGG
|
|
|
• increased frequency and number of plasma cells and germinal center B cells
|
|
|
• high total IgM serum levels for at least 50 weeks after immunization with hapten-carrier conjugate NP-CGG
• persistently high hapten-specific IgM levels for at least 50 weeks after immunization with hapten-carrier conjugate NP-CGG
|
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Ebf1tm1.1Rug mutation
(0 available);
any
Ebf1 mutation
(58 available)
Ighg1tm1(cre)Cgn mutation
(3 available);
any
Ighg1 mutation
(13 available)
|
|
|
immune system
|
|
• 2 to 3 times in immunized mice
|
hematopoietic system
|
|
• 2 to 3 times in immunized mice
|
Analysis Tools